Press Releases
-
01/19/11Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
-
12/15/10Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients with Refractory Metastatic Colorectal Cancer
-
11/17/10Jennerex Appoints Barry Sherman, M.D. to Board of Directors
-
10/21/10Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
-
09/13/10Jennerex Presents Positive Interim Data Using JX-594 and Sorafenib to Treat Liver Cancer
-
09/7/10Jennerex and Transgene Enter into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
- 08/25/10Jennerex Appoints Lara Longpre to Chief Operating Officer
-
08/19/10Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
-
06/22/10Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
-
05/20/10Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
-
05/13/10Key Clinical Data Regarding Jennerex's JX-594 to be Featured at American Society of Gene and Cell Therapy Meeting
-
04/28/10Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
-
04/19/10Positive Interim Results for JX-594 Randomized Phase 2 Liver Cancer Trial Presented at Major International Conference (EASL)
-
04/13/10Jennerex Completes Patient Enrollment in Phase 1 Trial for Intravenous Administration of JX-594
-
01/11/10Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
